News
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.
Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has initiated the long-term safety trial (the "Long-term Safety Trial") of KX-826, a potential first-in-class androgen receptor (AR) antagonist for the treatment of androgenetic alopecia (AGA) developed in-house, in China and has completed the first patient enrollment today.
Neurophet to unveil brain image analysis technology related to treatment of Alzheimer’s disease at AAIC 2023
Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the Alzheimer's Association International Conference (AAIC) 2023, which is held in Amsterdam, Netherlands.
SK Biopharmaceuticals Makes Big Bets to be ‘Big Biotech’
SK Biopharmaceuticals' Chief Executive Officer Donghoon Lee presented the new vision at a press conference in Seoul, Tuesday, introducing its plan to globalize and mobilize its therapeutic modalities and platforms of radiopharmaceutical therapy (RPT)[1] and targeted protein degradation (TPD)[2].
Ginkgo Bioworks and Sumitomo Chemical Announce Expanded Partnership To Develop Functional Chemicals with Synthetic Biology
Sumitomo Chemical Co., Ltd (TSE:4005), one of Japan's leading chemical companies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new program to develop functional chemicals with synthetic biology and expand upon the companies' existing biomanufacturing partnership.
Astellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on Welldoc’s Proven Digital Therapeutic Platform
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Eko Health Inc. (Co-Founder and CEO: Connor Landgraf, "Eko") announced today that they have entered into a License & Supply Agreement for the global supply and license of Eko's latest digital stethoscope, the CORE 500™, and a custom suite of Eko's AI-powered cardiovascular disease detection software.
Baird Medical Obtains NMPA Approval of Class III Registered Microwave Ablation Needle for Thyroid Nodules
Baird Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, announced today that the Company's independently developed and produced disposable MWA needle for the treatment of benign thyroid nodules received approval from China's National Medical Products Administration (the "NMPA") on July 13, 2023.
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara® (Ustekinumab).
GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development
On July 14, 2023, GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, signed a collaboration agreement.
CBC Group Appoints Billy Cho as Senior Managing Director, Private Equity and Co-Head, Joint Value Creation
CBC Group (“CBC”), Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, today announced the appointment of Billy Cho as Senior Managing Director, Private Equity and Co-Head, Joint Value Creation.
